Last updated: April 2026
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.
Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.
Quick Answer
- In studies examining hyperbaric oxygen therapy (HBOT) for post-traumatic stress disorder (PTSD), 30-39% of subjects experienced a severe but reversible increase in emotional symptoms when receiving the highest oxygen doses [https://pubmed.ncbi.nlm.nih.gov/38882688/].
- For patients with acute ischemic stroke, a meta-analysis showed no statistically significant difference in adverse event incidence within six months of follow-up, with an odds ratio (OR) of 0.98 (95%CI = 0.25 to 3.79) when comparing HBOT to control groups [https://pubmed.ncbi.nlm.nih.gov/38308217/].
- Other side effects observed in PTSD studies were generally transient and minor, suggesting that most reactions to HBOT are not long-lasting or severe [https://pubmed.ncbi.nlm.nih.gov/38882688/].
- Notably, HBOT demonstrated a significant reduction in adverse event incidence at the end of treatment for acute ischemic stroke patients, with an OR of 0.42 (95%CI = 0.19 to 0.94) compared to control groups, indicating a potentially favorable short-term safety profile [https://pubmed.ncbi.nlm.nih.gov/38308217/].
Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized chamber, a process that can significantly increase oxygen delivery to the body's tissues. When we analyze the safety profile of HBOT based on published clinical trials, a nuanced picture emerges regarding potential complications. While many side effects are mild and temporary, specific conditions and higher dosages can lead to more pronounced, yet often reversible, reactions. For instance, in studies focusing on post-traumatic stress disorder (PTSD), a notable percentage of individuals, specifically 30-39% of subjects, experienced a severe but reversible exacerbation of emotional symptoms when treated with the highest oxygen doses [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This observation highlights the importance of dosage in managing patient responses. Conversely, research into acute ischemic stroke has shown a favorable safety profile for HBOT in some aspects, with a meta-analysis indicating no statistically significant difference in adverse events within six months post-treatment, reporting an odds ratio (OR) of 0.98 (95%CI = 0.25 to 3.79) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This suggests that for certain conditions, HBOT can be an adjunctive therapy without significantly increasing long-term adverse event rates. See the stroke recovery evidence atlas for the full investigational evidence breakdown.
What are the common side effects of HBOT?
Most side effects associated with hyperbaric oxygen therapy (HBOT) are transient and minor. These temporary reactions typically resolve on their own without lasting impact, reflecting the body's adaptation to the pressurized oxygen environment. However, at higher oxygen doses, particularly in specific patient populations, more noticeable side effects can occur.
Transient and Minor Reactions
In our review of various studies, we consistently find reports of side effects that are not severe. These might include ear discomfort due to pressure changes, temporary changes in vision, or sinus pain. These issues are often manageable through proper training in pressure equalization techniques and careful monitoring by clinical staff. For example, during treatments for post-traumatic stress disorder (PTSD), while higher doses led to more significant emotional responses, other side effects were noted as "transient and minor" [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This suggests that the majority of patients undergoing HBOT will experience only mild, temporary discomforts rather than severe physical complications. The reversible nature of these minor side effects is a key aspect of HBOT's overall safety profile, allowing clinicians to adjust treatment protocols as needed to minimize patient discomfort.
Emotional Symptom Exacerbation at High Doses
A more significant side effect, specifically observed in the context of treating post-traumatic stress disorder (PTSD), is a temporary increase in emotional symptoms. This reaction is particularly relevant when patients receive higher oxygen doses. In a systematic review and dosage analysis of HBOT for PTSD, researchers found that the "greater symptomatic response was accompanied by a greater and severe reversible exacerbation of emotional symptoms at the highest oxygen doses in 30-39% of subjects" [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This means that a substantial portion of patients, nearly one-third to two-fifths, might experience a temporary worsening of their emotional state, such as increased anxiety or irritability, during or immediately after high-dose HBOT sessions. It is crucial to emphasize that this exacerbation is described as "reversible," meaning these symptoms subside over time. Clinicians must be aware of this potential reaction and adequately prepare patients for it, ensuring support systems are in place. The observation points to a specific dose-response relationship where the therapeutic benefits of higher oxygen doses might come with a temporary emotional cost.
Managing Side Effects
Effective management of HBOT side effects involves careful patient selection, individualized treatment plans, and thorough pre-treatment education. Patients are often taught techniques to equalize pressure in their ears to prevent barotrauma, a common minor complaint. For emotional exacerbations, particularly in PTSD patients, close monitoring and psychological support are essential. The reversible nature of the more severe emotional symptoms means that while they can be distressing, they are not permanent. This highlights the importance of a skilled clinical team who can guide patients through their treatment journey, addressing any complications promptly and effectively. The overall safety of HBOT, when administered under proper medical supervision, relies on understanding and mitigating these known side effects.
How does HBOT dosage affect safety in PTSD treatment?
The dosage of hyperbaric oxygen therapy (HBOT) plays a critical role in both the efficacy and safety profile of the treatment, especially in conditions like post-traumatic stress disorder (PTSD). Our analysis of published trials reveals a clear link between the cumulative oxygen dose and the nature of symptomatic improvements, as well as the occurrence of certain side effects. Higher cumulative oxygen doses are directly associated with more significant emotional side effects, even as they may also lead to greater symptomatic improvements.
Dose-Response Relationship for Symptomatic Improvement
In studies investigating HBOT for PTSD, a linear dose-response relationship has been identified. This means that as the total amount of oxygen delivered to the patient increases, so does the level of symptomatic improvement. Specifically, researchers observed increased symptomatic improvement with increasing cumulative oxygen dose, ranging from 1002 to 11,400 atmosphere-minutes of oxygen [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This finding suggests that for patients with PTSD, receiving a higher overall dose of oxygen across multiple sessions can lead to more pronounced positive changes in their symptoms. The therapy typically involves 40-60 HBOT sessions, administered over a wide range of pressures from 1.3 to 2.0 ATA. This broad range of effective pressures and oxygen doses allows for flexibility in treatment protocols, tailoring the therapy to individual patient needs while aiming for optimal outcomes. Systematic review of HBOT for PTSD highlights how careful titration of oxygen dose can maximize benefits.
Increased Emotional Side Effects with Higher Doses
While higher doses are linked to greater symptomatic improvement, they also come with a notable safety consideration: an increased risk of severe, albeit reversible, emotional symptom exacerbation. This specific side effect was observed in 30-39% of subjects who received the highest oxygen doses in PTSD treatment trials [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This means that nearly one-third to two-fifths of patients undergoing high-dose HBOT for PTSD may experience a temporary but significant worsening of their emotional state, such as heightened anxiety, irritability, or distress. It is crucial for clinicians to carefully weigh the potential for greater symptomatic improvement against the increased likelihood of these temporary emotional challenges. Patient education and robust psychological support during high-dose regimens become even more vital to manage these anticipated reactions. The temporary nature of these exacerbations is a key factor, as symptoms are expected to subside after the treatment period.
Optimizing Dosage for Safety and Efficacy
The challenge for practitioners lies in finding the optimal balance between achieving the best therapeutic outcomes and minimizing adverse reactions. The existence of a linear dose-response relationship for improvement suggests that higher doses could be more effective, but the concurrent increase in emotional side effects demands careful consideration. Treatment protocols must be designed to gradually increase dosage if necessary, allowing patients to adapt and monitoring their responses closely. For example, starting with lower pressures and gradually increasing them, or carefully managing the total cumulative oxygen exposure, could help mitigate the risk of severe emotional exacerbations. The wide range of effective pressures (1.3 to 2.0 ATA) and oxygen doses (1002 to 11,400 atmosphere-minutes) provides clinicians with options to customize treatment. The evidence suggests that while HBOT offers significant benefits for PTSD, particularly at higher doses, a personalized approach to dosage is essential to ensure patient safety and comfort.
Is HBOT safe for acute ischemic stroke patients?
Hyperbaric oxygen therapy (HBOT) has been investigated as an adjunctive treatment for acute ischemic stroke (AIS) to improve outcomes. Our review of the safety data from published trials indicates a generally favorable safety profile for HBOT in this patient population, with specific findings regarding adverse event incidence both during and after treatment. Overall, HBOT does not appear to significantly increase the long-term risk of adverse events for AIS patients.
Adverse Event Incidence During Treatment
A systematic review and meta-analysis specifically evaluating the efficacy and safety of adjunctive HBOT in acute ischemic stroke patients included eight studies involving 493 patients. This comprehensive analysis found that HBOT showed a significant improvement in adverse event incidence at the end of treatment compared to the control group. The odds ratio (OR) was 0.42, with a 95% confidence interval (CI) of 0.19 to 0.94 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This statistic suggests that during the immediate treatment phase, patients receiving HBOT for AIS actually experienced fewer adverse events than those in control groups (who received no HBOT or sham HBOT). This finding is significant because it indicates that HBOT, far from introducing new immediate risks, might actually contribute to a safer acute treatment phase for stroke patients. The specific types of adverse events considered in this context typically include complications directly related to the treatment or the acute phase of stroke management.
Long-Term Adverse Event Incidence
Beyond the immediate treatment period, the meta-analysis also examined the incidence of adverse events over a longer follow-up period, specifically within six months. The results showed no statistically significant differences between the HBOT group and the control group in terms of adverse event incidence within this timeframe. The odds ratio was 0.98, with a 95% confidence interval of 0.25 to 3.79 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This indicates that receiving HBOT as an adjunctive therapy for AIS does not appear to increase the risk of adverse events over the medium term (up to six months post-treatment). This finding is crucial for establishing the overall safety of HBOT, assuring clinicians and patients that the therapy does not contribute to a higher rate of complications in the months following acute stroke management. Efficacy and safety of HBOT in acute ischemic stroke provides detailed statistical analysis supporting this conclusion.
Broader Safety Considerations for AIS Patients
While the meta-analysis focused on general adverse event incidence, it's important to consider the specific vulnerabilities of acute ischemic stroke patients. These individuals often have complex medical histories and are at risk for various complications related to their stroke. The fact that HBOT did not increase adverse events within six months, and even showed a reduction during the treatment phase, is a strong indicator of its safety in this fragile population. The study looked at several biomarkers and clinical scores, including NIHSS score, Barthel index, TNF-α, sICAM, sVCAM, sE-selectin, and CRP, finding no statistically significant differences between groups for most of these measures, further supporting a neutral to positive safety profile for HBOT in AIS. This suggests that HBOT can be integrated into existing stroke management protocols without adding significant burdens in terms of patient safety.
What studies are currently investigating HBOT safety for brain injury?
Several clinical trials are actively investigating the safety and efficacy of hyperbaric oxygen therapy (HBOT) for traumatic brain injury (TBI). These studies are crucial for building a robust evidence base for HBOT's role in neurorehabilitation and for clearly defining its safety parameters in this patient population. Many of these trials employ rigorous methodologies, often comparing active HBOT to inactive or placebo HBOT to isolate the true effects of the treatment.
Ongoing Clinical Trials for Traumatic Brain Injury
One notable ongoing investigation is the Hyperbaric Oxygen Brain Injury Treatment Trial, listed under the identifier NCT02407028 on ClinicalTrials.gov [https://clinicaltrials.gov/study/NCT02407028]. This randomized clinical trial aims to determine whether HBOT can effectively reduce symptoms following a traumatic brain injury. The study specifically targets U.S. Service Members, Veterans, and Active-Duty Military personnel aged 18-75 years, who have experienced a mild or moderate TBI or concussion at least one year prior to participation. The trial's design involves comparing active HBOT with an inactive (placebo) HBOT, which is a common and robust method for evaluating treatment effectiveness and safety in a blinded manner. This particular trial, also highlighted on the HBOT.USF.edu website, seeks to provide definitive answers regarding the potential benefits and any associated risks of HBOT for persistent symptoms after brain injury [https://hbot.usf.edu/]. The results from such trials are vital for informing clinical practice and establishing HBOT as a safe and effective intervention for TBI.
Placebo-Controlled and Randomized Designs
The use of randomized, double-blind, placebo-controlled designs is a hallmark of high-quality clinical research, especially when evaluating interventions like HBOT. In these types of studies, neither the patient nor the researchers administering the treatment know whether the patient is receiving the active therapy or a sham (inactive) version. This minimizes bias and allows for a clearer assessment of the treatment's true effects, including its safety profile. For example, a double-blind randomized trial on hyperbaric oxygen for persistent symptoms after brain injury, published in Nature.com, underlines the importance of such rigorous study designs [https://www.nature.com/articles/s41598-025-86631-6]. By comparing active HBOT to a placebo, researchers can accurately differentiate between real physiological effects and psychological or expectation-based responses. This is particularly important when evaluating potential side effects, as it helps determine if reported complications are directly attributable to the oxygen and pressure or to other factors.
Importance of Military and Veteran Populations
Many of the ongoing trials, including NCT02407028, focus specifically on military and veteran populations. This emphasis is due to the high incidence of traumatic brain injury and post-concussion syndrome within these groups, often sustained during combat or training. Studying these specific cohorts allows researchers to address the unique challenges and symptom presentations common in service members. The findings from trials involving these populations are not only critical for improving the care of veterans but also contribute valuable data to the broader understanding of TBI and HBOT safety across different patient demographics. HBOT for traumatic brain injury clinical trial is a prime example of this focused research effort. The continuous evaluation through such studies is essential for confirming the long-term safety and efficacy of HBOT in brain injury recovery.
How reliable are the studies on HBOT safety?
The reliability of studies investigating hyperbaric oxygen therapy (HBOT) safety is a critical factor in understanding its true risk profile. In our assessment, we prioritize studies that employ rigorous methodologies, such as randomized controlled trials, and those that undergo systematic quality evaluations. Many published trials on HBOT, particularly in areas like post-traumatic stress disorder (PTSD), demonstrate a high level of methodological quality, contributing to the trustworthiness of their safety findings.
Quality Assessment in PTSD Research
When we examine the research on HBOT for PTSD, we find that a significant number of studies meet high quality standards. A systematic review and dosage analysis of HBOT efficacy in PTSD included eight studies, seven of which were randomized trials [https://pubmed.ncbi.nlm.nih.gov/38882688/]. The methodological quality and bias of these studies were determined using the PEDro Scale, a widely recognized tool for assessing the quality of physical therapy and other intervention trials. All seven randomized trials included in this review were found to be of "good-highest quality" by PEDro scale scoring [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This high quality rating means that these studies were well-designed, adequately controlled for bias, and their results are more likely to be reliable. Such rigorous evaluation enhances the confidence we can place in their reported safety profiles, including the observation that 30-39% of subjects experienced severe but reversible emotional exacerbation at high oxygen doses.
Meta-Analyses and Comprehensive Reviews
Beyond individual high-quality trials, the field benefits from systematic reviews and meta-analyses, which synthesize findings from multiple studies. These comprehensive analyses provide a broader and often more statistically powerful perspective on safety. For instance, the systematic review and meta-analysis on the efficacy and safety of HBOT in acute ischemic stroke combined data from eight studies involving 493 patients [https://pubmed.ncbi.nlm.nih.gov/38308217/]. The independent data extraction and assessment performed by two researchers, along with the use of the Cochrane Collaboration's tool for quality evaluation, underscore the commitment to robust analysis. The conclusions drawn from such meta-analyses, like the finding of no statistically significant differences in adverse event incidence within six months for stroke patients, are highly reliable due to the aggregated data and systematic approach.
Transparency in Reporting Conflicts of Interest
Another aspect contributing to the reliability of studies is transparency regarding potential conflicts of interest. Researchers in the field often disclose any affiliations that could influence their work. For example, in the systematic review on HBOT for PTSD, Susan R Andrews stated she is self-employed in a private practice of neuropsychology, and P Harch is employed by Harch Hyperbarics, Inc. [https://pubmed.ncbi.nlm.nih.gov/38882688/]. Such disclosures are standard practice and allow readers to consider any potential biases, thereby contributing to the overall transparency and perceived reliability of the research. When studies are conducted with strong methodological designs, undergo rigorous quality assessments, and maintain transparency, the findings regarding HBOT safety become much more dependable for informing clinical decisions.
What are the most serious potential side effects of HBOT?
The most serious potential side effects of hyperbaric oxygen therapy (HBOT) are generally rare but include barotrauma, oxygen toxicity, and, in specific cases, a severe reversible exacerbation of emotional symptoms. While most side effects are minor, understanding these more significant possibilities is crucial for patient safety.
Barotrauma and Oxygen Toxicity
Barotrauma refers to tissue damage caused by pressure changes, most commonly affecting the ears, sinuses, or lungs. Middle ear barotrauma is the most frequent adverse event, often manifesting as ear fullness or pain, and can be mitigated by proper equalization techniques. Pulmonary barotrauma, though rare, can lead to pneumothorax (collapsed lung). Oxygen toxicity, another serious concern, can affect the central nervous system (CNS) or the lungs. CNS oxygen toxicity can cause seizures, typically at higher pressures and longer exposure times, while pulmonary oxygen toxicity leads to lung inflammation and reduced lung capacity over prolonged treatments. These risks are carefully managed by adhering to established treatment protocols that limit pressure, oxygen concentration, and exposure duration, as outlined in standard HBOT guidelines.
Emotional Symptom Exacerbation
For patients undergoing HBOT for post-traumatic stress disorder (PTSD), a significant emotional side effect has been observed at higher oxygen doses. "The highest doses were associated with a severe reversible exacerbation of emotional symptoms in 30-39% of subjects," according to Susan R Andrews et al., from their 2024 review [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This means that nearly one-third to two-fifths of patients may experience a temporary but intense worsening of their emotional state, such as increased anxiety, panic, or irritability. While distressing, this effect is described as "reversible," meaning symptoms subside after the treatment. This particular side effect, though not physically dangerous in the same way as barotrauma or oxygen toxicity, can be highly impactful on a patient's mental well-being during treatment and requires careful monitoring and psychological support.
Risk Mitigation Strategies
To minimize the risk of serious side effects, HBOT is always administered under medical supervision. Patient screening identifies contraindications such as untreated pneumothorax or certain lung conditions. During treatment, trained personnel monitor patients closely for any signs of discomfort or adverse reactions. Pressure changes are gradual, and oxygen exposure is carefully controlled to stay within safe limits. For conditions like PTSD, where emotional exacerbation is a known risk at higher doses, clinicians must conduct thorough psychological assessments and prepare patients for potential emotional fluctuations, ensuring they have adequate coping mechanisms and support. The overall safety of HBOT relies on these stringent protocols and individualized patient care.
Is HBOT safe for long-term use?
The long-term safety of hyperbaric oxygen therapy (HBOT) is an area of ongoing research, with current evidence suggesting that for certain conditions, HBOT does not significantly increase adverse events over several months post-treatment. However, specific long-term effects can vary depending on the condition being treated, the dosage, and the individual patient's health.
Long-Term Monitoring in Acute Ischemic Stroke
For patients with acute ischemic stroke (AIS), a systematic review and meta-analysis provided insights into HBOT's safety over a medium-term period. This analysis, which included 8 studies and 493 patients, found "no statistically significant differences between HBOT and the control group in terms of adverse event incidence within ≤ 6 months of follow-up (OR = 0.98, 95%CI = 0.25 to 3.79)" [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This indicates that, for this specific patient population, receiving HBOT did not lead to a higher rate of complications in the six months following treatment compared to control groups. This finding is reassuring for patients and clinicians, suggesting that HBOT does not introduce new or increased risks of adverse events in the months after acute stroke care.
Chronic Conditions and Repeated Treatments
When considering long-term use, it's important to distinguish between a single course of treatment for an acute condition and repeated, ongoing treatments for chronic conditions. While the data for AIS suggests safety over six months, the effects of HBOT over years are less extensively documented in large-scale randomized controlled trials. For conditions requiring repeated courses of HBOT, such as certain chronic wounds or radiation injuries, the cumulative effects of oxygen exposure and pressure changes on organs like the lungs and eyes are continually monitored. The transient and minor nature of most side effects observed in studies, such as those for PTSD where "other side effects were transient and minor" [https://pubmed.ncbi.nlm.nih.gov/38882688/], generally suggests that short-to-medium term repeated exposures are well-tolerated. However, continuous assessment by a healthcare provider is essential for any long-term HBOT regimen.
Considerations for Eye and Lung Health
Potential long-term concerns with HBOT can include reversible changes in vision (myopia) and, less commonly, cataracts with very prolonged or repeated high-dose exposures. Pulmonary effects, while typically reversible, could theoretically accumulate with excessive long-term use, though standard protocols are designed to prevent this. The medical community continues to collect data on these aspects. The current evidence supports the safety of HBOT for defined treatment protocols, particularly when administered under strict medical guidance and monitoring. For conditions where long-term or repeated HBOT is considered, the decision should be made based on a careful risk-benefit analysis by a qualified healthcare professional, taking into account the individual patient's overall health and the specific therapeutic goals.
How do HBOT side effects compare to other treatments?
Comparing hyperbaric oxygen therapy (HBOT) side effects to those of other treatments is complex, as it depends heavily on the specific condition being treated and the alternative therapies available. However, based on published trials, HBOT's side effect profile often involves transient and minor issues, with some notable exceptions for higher doses.
Comparison in PTSD Treatment
For post-traumatic stress disorder (PTSD), alternative treatments often include psychotherapy (e.g., Cognitive Behavioral Therapy, Eye Movement Desensitization and Reprocessing) and pharmacotherapy (e.g., SSRIs, SNRIs). These treatments have their own side effect profiles. Psychotherapy can sometimes lead to temporary emotional distress as individuals confront traumatic memories, while medications can cause a range of systemic side effects like nausea, weight gain, sexual dysfunction, or sedation. In contrast, HBOT for PTSD, while showing symptomatic improvements, was associated with a "severe reversible exacerbation of emotional symptoms at the highest oxygen doses in 30-39% of subjects" [https://pubmed.ncbi.nlm.nih.gov/38882688/]. Other HBOT side effects were "transient and minor." This suggests that while HBOT has unique side effects like emotional surges, these are often temporary and localized, contrasting with the systemic effects of many psychiatric medications. The choice of treatment often involves weighing these distinct risk-benefit profiles.
Comparison in Acute Ischemic Stroke
In acute ischemic stroke (AIS), standard treatments include thrombolytics (clot-busting drugs) and mechanical thrombectomy. Thrombolytics carry a significant risk of bleeding, including intracranial hemorrhage, which can be life-threatening. Mechanical thrombectomy involves invasive procedures with risks of vessel damage or infection. When HBOT is considered as an adjunctive therapy for AIS, its safety profile appears favorable in comparison. A meta-analysis found "no statistically significant differences between HBOT and the control group in terms of adverse event incidence within ≤ 6 months of follow-up (OR = 0.98, 95%CI = 0.25 to 3.79)" [https://pubmed.ncbi.nlm.nih.gov/38308217/]. Furthermore, HBOT actually showed a "significant improvement in adverse event incidence at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94)" compared to control groups. This suggests that HBOT, when used alongside standard care, does not add to the long-term adverse event burden and may even reduce immediate adverse events, making it a potentially safer adjunctive option compared to some more invasive or pharmacologically potent alternatives.
General Considerations
Generally, HBOT's most common side effects are related to pressure changes (e.g., ear or sinus discomfort) or oxygen exposure (e.g., temporary vision changes, rare oxygen toxicity seizures). These are distinct from the systemic side effects seen with many pharmacological treatments or the risks associated with invasive surgical procedures. "The greater symptomatic response was accompanied by a greater and severe reversible exacerbation of emotional symptoms at the highest oxygen doses in 30-39% of subjects. Other side effects were transient and minor," noted Susan R Andrews et al. [https://pubmed.ncbi.nlm.nih.gov/38882688/]. While HBOT requires specialized equipment and trained personnel, its localized and often reversible side effects can make it an attractive option when compared to therapies with more pervasive or irreversible systemic risks, especially for conditions where it demonstrates clear efficacy.
Are there specific conditions where HBOT is considered less safe?
While hyperbaric oxygen therapy (HBOT) is generally safe when administered under proper medical supervision, there are specific conditions and circumstances where its use is considered less safe or contraindicated. These situations primarily involve pre-existing medical conditions that could be exacerbated by pressure changes or high oxygen levels.
Absolute Contraindications
The most critical absolute contraindication for HBOT is an untreated pneumothorax (collapsed lung). The pressure changes within the hyperbaric chamber can cause the pneumothorax to expand, leading to a tension pneumothorax, which is a life-threatening medical emergency. Therefore, any patient with a suspected or confirmed pneumothorax must have it treated before undergoing HBOT. Other conditions that may be considered absolute contraindications or require extreme caution include certain types of lung disease, such as severe obstructive pulmonary disease with air trapping, due to the increased risk of pulmonary barotrauma. Additionally, individuals who have recently undergone certain ear or sinus surgeries may need to wait until full healing occurs before HBOT to avoid complications from pressure changes.
Relative Contraindications and Precautions
Several conditions are considered relative contraindications, meaning HBOT can be administered but with increased caution and specific precautions. These include upper respiratory infections, which can make ear equalization difficult and increase the risk of barotrauma. Chronic sinusitis or ear infections also fall into this category. Patients with uncontrolled high fever or seizure disorders require careful assessment, as HBOT can potentially lower the seizure threshold in susceptible individuals, particularly with central nervous system oxygen toxicity. Pregnancy is generally considered a relative contraindication, and HBOT is typically reserved for life-threatening conditions where the benefits outweigh potential risks to the fetus. The presence of claustrophobia is also a consideration, as patients must remain in a confined space for the duration of the treatment.
Dosage Considerations for Emotional Exacerbation
While not a contraindication in itself, the risk of "severe reversible exacerbation of emotional symptoms" in 30-39% of subjects at the highest oxygen doses for PTSD treatment [https://pubmed.ncbi.nlm.nih.gov/38882688/] highlights a specific safety concern related to dosage for a particular patient group. This means that while HBOT may be therapeutic for PTSD, the administration of very high oxygen doses should be approached with caution, ensuring adequate psychological support and patient preparation to manage these temporary emotional surges. Clinicians must carefully weigh the potential for greater symptomatic improvement at higher doses against the increased likelihood of these emotional challenges, tailoring the treatment plan to the individual's psychological resilience. The individualized approach is key to ensuring that HBOT remains a safe and effective treatment even when specific risks are identified.
What should I do if I experience side effects during HBOT?
If you experience side effects during hyperbaric oxygen therapy (HBOT), your immediate action should be to communicate with the HBOT chamber operator or supervising medical staff. They are trained to monitor patients and manage any adverse reactions that may arise during treatment.
Immediate Communication with Staff
The most important step is to alert the HBOT chamber operator or attending medical professional as soon as you notice any discomfort or unusual symptoms. HBOT chambers are equipped with communication systems, allowing patients to speak with staff outside the chamber at all times. Do not try to endure discomfort silently. Common minor side effects, such as ear fullness, pain, or pressure, can often be alleviated with simple techniques like yawning, swallowing, or specific breathing exercises, which the staff can guide you through. For example, in studies on PTSD, "other side effects were transient and minor" [https://pubmed.ncbi.nlm.nih.gov/38882688/], and these are generally manageable with prompt communication.
Reporting and Assessment
Upon reporting a side effect, the medical staff will assess its severity and nature. They will determine if the treatment needs to be paused, adjusted, or stopped. For instance, if you experience significant ear pain that doesn't resolve with equalization, the pressure in the chamber might be slowly reduced to alleviate the discomfort. In cases of more serious symptoms, such as severe dizziness, visual changes, or unusual neurological signs, the staff is prepared to abort the dive and provide immediate medical attention. The safety protocols in HBOT clinics are designed to handle a range of potential complications, from minor barotrauma to rare instances of oxygen toxicity.
Post-Treatment Follow-up
Even if side effects are mild and resolve during the session, it is important to discuss them with your healthcare provider after the treatment. This allows the medical team to adjust future HBOT sessions, if necessary, or to provide advice on managing lingering symptoms. For example, if you experienced a "severe reversible exacerbation of emotional symptoms" during a high-dose HBOT for PTSD, as observed in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/38882688/], your care team might consider modifying the oxygen dose or pressure for subsequent sessions, or provide additional psychological support. Documenting and discussing any side effects ensures that your HBOT treatment remains as safe and effective as possible, tailored to your individual response.
Frequently Asked Questions
What are the most serious potential side effects of HBOT?
The most serious potential side effects of HBOT include barotrauma, which is tissue damage from pressure changes (most commonly affecting ears or sinuses, but rarely lungs), and oxygen toxicity, which can lead to seizures or lung inflammation. Additionally, in studies for PTSD, 30-39% of subjects experienced a severe but reversible exacerbation of emotional symptoms at the highest oxygen doses [https://pubmed.ncbi.nlm.nih.gov/38882688/]. These risks are managed through careful patient screening, controlled treatment protocols, and continuous monitoring by trained medical staff.
Is HBOT safe for long-term use?
The long-term safety of HBOT is still being studied, but current evidence suggests it does not significantly increase adverse events over several months. For acute ischemic stroke, a meta-analysis found no statistically significant difference in adverse event incidence within six months of follow-up (OR = 0.98, 95%CI = 0.25 to 3.79) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. For chronic conditions requiring repeated treatments, careful monitoring for cumulative effects on vision and lung function is essential, though most side effects are transient and minor.
How do HBOT side effects compare to other treatments?
HBOT side effects are generally localized and often reversible, such as ear discomfort or temporary emotional surges in PTSD patients. In contrast, many pharmacological treatments can cause systemic side effects (e.g., nausea, fatigue, organ damage), and surgical interventions carry risks like infection or bleeding. For acute ischemic stroke, HBOT showed a significant improvement in adverse event incidence at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94) compared to control, suggesting a favorable safety profile relative to invasive alternatives [https://pubmed.ncbi.nlm.nih.gov/38308217/].
Are there specific conditions where HBOT is considered less safe?
Yes, HBOT is considered less safe or contraindicated for certain conditions. An untreated pneumothorax (collapsed lung) is an absolute contraindication due to the risk of exacerbation under pressure. Relative contraindications include severe lung diseases with air trapping, recent ear/sinus surgery, uncontrolled fever, or seizure disorders. While not a contraindication, the risk of severe emotional exacerbation at high doses for PTSD patients (30-39% of subjects) necessitates careful psychological assessment and support [https://pubmed.ncbi.nlm.nih.gov/38882688/].
What should I do if I experience side effects during HBOT?
If you experience any side effects during HBOT, you should immediately communicate with the HBOT chamber operator or supervising medical staff. They are trained to assess your symptoms and take appropriate action, which may include guiding you through pressure equalization techniques, adjusting the chamber pressure, or, if necessary, pausing or stopping the treatment. All HBOT chambers have communication systems for this purpose.
Sources
- https://pubmed.ncbi.nlm.nih.gov/38882688/
- https://pubmed.ncbi.nlm.nih.gov/38308217/
- https://clinicaltrials.gov/study/NCT02407028
- https://hbot.usf.edu/
- https://www.nature.com/articles/s41598-025-86631-6
Related Reading
- HBOT Side Effects and Safety: What to Expect
- HBOT for Elderly Patients: Safety Considerations
- HBOT Common Beginner Mistakes
- HBOT for Glaucoma and Retinal Conditions
- HBOT for PTSD: Clinical Trials Update 2026
— The HBOT Finder Team